High Sensitive IFN gamma ELISA Assay

Insulin-Like Growth Factor Binding Protein-1 ELISA

$275.00

The IGFBP-1 ELISA Assay Kit (enzyme-linked immunoassay kit) is intended for the quantitative determination of Insulin-Like Growth Factor Binding Protein-1in human serum. The Eagle Biosciences IGFBP-1 ELISA Assay Kit is for research use only and not to be used in diagnostic procedures.

SKU: BP131-K01 Categories: , ,

Insulin-Like Growth Factor Binding Protein-1 ELISA

The Insulin-Like Growth Factor Binding Protein-1 ELISA is For Research Use Only

Size: 1×96 wells
Sensitivity: 0.5 μg/L
Dynamic Range: 1–250 μg/L
Incubation Time: 75 minutes
Sample Type: Serum
Sample Size: 25 µL
Alternative Names: Human Insulin-Like Grwoth Factor Binding Protein-1, Human IGFBP-1, IGFBP1, IGFBP-1
Controls Included

Assay Principle

The principle of the following enzyme immunoassay test follows a typical two-step capture or ‘sandwich’ type assay. The assay makes use of two highly specific monoclonal antibodies: A monoclonal antibody specific for IGFBP-1 is immobilized onto the microplate and another monoclonal antibody specific for a different region of IGFBP-1 is conjugated to horse radish peroxidase (HRP). IGFBP-1 from the sample and standards are allowed to bind to the plate, washed, and subsequently incubated with the HRP conjugate. After a second washing step, the enzyme substrate is added. The enzymatic reaction is terminated by addition of the stopping solution. The absorbance is measured on a microtiter plate reader. The intensity of the colour formed by the enzymatic reaction is directly proportional to the concentration of IGFBP-1 in the sample. A set of standards is used to plot a standard curve from which the amount of IGFBP-1 in patient samples and controls can be directly read.

Related Products

SHBG ELISA
Growth Hormone (hGH) ELISA Assay
IGFBP-6 ELISA Kit

Additional Information

Assay Background

Insulin-like growth factor binding protein-1 (IGFBP-1) is one of six proteins that specifically bind insulin-like growth factors I and II (IGF-I and IGF-II) in body fluids and tissues. IFGBP-1 contains 234 amino acids, with a predicted molecular mass of 25 kDa. The major sites of IGFBP-1 synthesis are the fetal /adult liver and decidualized endometrium. Serum levels of IGFBP-1, which reflect its synthesis by the liver, exhibit considerable diurnal variation. Circulating IGFBP-1 levels are highest early in the morning and lowest in the evening. The levels are high in the fetus and newborn, but decline steadily until puberty. The mean level of IGFBP-1 in healthy adults is 4.4 μg/L (range 0.6–14.4 μg/L). After about 65 years of age, serum IGFBP-1 levels begin to increase. There is also an inverse correlation between body mass index (BMI) and fasting serum IGFBP-1 concentrations. The most important regulator of circulating IGFBP-1 is insulin. Fasting insulin and IGFBP-1 concentrations are inversely correlated. During a 3-h glucose tolerance test, there is a decrease of about 50% in serum IFGBP-1 levels. Eating a meal also has a decreasing effect. In insulin-dependent diabetes (IDDM), serum IGFBP-1 levels are elevated. In non-insulin dependent diabetes, in which insulin levels are high, serum IGFBP-1 is decreased. Low levels of IGFBP-1 have also been observed in the following cases: acromegaly, Cushing’s syndrome and polysystic ovarian syndrome (PCO).

Package Inserts

 

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations